Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

GNLX

Genelux Corp

May 01 • 04:00PM ET

3.28

Dollar change +0.17
Percentage change 5.47	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM VTWO IWN SCHA IWC IWO CNCR VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.10	Insider Own	25.90%	Shs Outstand	26.79M	Perf Week	-4.93%
Market Cap	88.13M	Forward P/E	-	EPS next Y	-1.18	Insider Trans	-3.89%	Shs Float	19.91M	Perf Month	-37.52%
Income	-28.30M	PEG	-	EPS next Q	-0.22	Inst Own	21.69%	Short Float	10.22%	Perf Quarter	-69.00%
Sales	0.17M	P/S	518.43	EPS this Y	24.78%	Inst Trans	-	Short Ratio	14.47	Perf Half Y	-76.33%
Book/sh	0.73	P/B	4.51	EPS next Y	-35.24%	ROA	-169.32%	Short Interest	2.03M	Perf Year	-86.89%
Cash/sh	0.86	P/C	3.80	EPS next 5Y	-	ROE	-	52W Range	3.06 - 40.98	Perf YTD	-76.59%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-23.84%	ROI	-132.61%	52W High	-92.00%	Beta	-1.25
Dividend TTM	-	Quick Ratio	3.69	Sales past 5Y	-24.62%	Gross Margin	-498.82%	52W Low	7.19%	ATR (14)	0.43
Dividend Ex-Date	-	Current Ratio	3.69	EPS Y/Y TTM	-412.24%	Oper. Margin	-14214.71%	RSI (14)	31.85	Volatility	8.50% 10.84%
Employees	23	Debt/Eq	0.13	Sales Y/Y TTM	-98.46%	Profit Margin	-16645.29%	Recom	1.00	Target Price	26.00
Option/Short	No / Yes	LT Debt/Eq	0.10	EPS Q/Q	-77.51%	Payout	-	Rel Volume	1.14	Prev Close	3.11
Sales Surprise	-	EPS Surprise	-33.33%	Sales Q/Q	-100.00%	Earnings	Apr 01 BMO	Avg Volume	140.59K	Price	3.28
SMA20	-16.69%	SMA50	-40.47%	SMA200	-77.69%	Trades		Volume	160,323	Change	5.47%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-27-23	Initiated	H.C. Wainwright	Buy	$35
Sep-12-23	Initiated	Maxim Group	Buy	$40
Feb-15-23	Initiated	The Benchmark Company	Speculative Buy	$10

Apr-26-24 09:35AM	Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Apr-23-24 09:35AM	Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Apr-05-24 09:35AM	After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX) (Zacks)
Apr-04-24 12:00PM	All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy (Zacks)
Apr-02-24 07:52AM	GNLX Stock Earnings: Genelux Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Loading…
Apr-01-24 07:00AM	Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -18.51%
Dec-15-23 03:01PM	Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX) (GuruFocus.com) -13.23%
Nov-27-23 07:00AM	Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer (GlobeNewswire)
Nov-14-23 05:50PM	Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates (GlobeNewswire)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-11-23 09:00AM	Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment (PR Newswire)
Sep-19-23 03:01PM	Director John Thomas Sells 6667 Shares of Genelux Corp (GNLX) (GuruFocus.com) +8.04%
Sep-15-23 03:03PM	Director John Smither Sells 900 Shares of Genelux Corp (GNLX) (GuruFocus.com)
Sep-14-23 01:21PM	10% Owner Aladar Szalay Sells 52,616 Shares of Genelux Corp (GNLX) (GuruFocus.com)
07:00AM	Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:01PM	Loading…
Sep-07-23 04:01PM	Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-28-23 07:00AM	Genelux Corporation Announces New Chief Financial Officer (GlobeNewswire) +11.01%
Aug-14-23 07:00AM	Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates (GlobeNewswire)
Aug-02-23 04:00PM	Genelux Corporation to Participate in Fireside Chat at BTIGs Virtual Biotechnology Conference 2023 (GlobeNewswire)
01:08AM	10 Recent IPOs in 2023 to Consider (Insider Monkey)
Jul-28-23 10:54AM	Why Shares of Genelux Climbed This Week (Motley Fool) -9.38%
Jul-20-23 04:45PM	Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires (GlobeNewswire) -10.85%
Jul-10-23 07:00AM	Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology (GlobeNewswire)
Jun-29-23 07:00AM	Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics, LLC (GlobeNewswire)
Jun-22-23 07:00AM	Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023 (GlobeNewswire) -7.05%
Jun-12-23 07:00AM	Genelux Corporation Announces $18 Million Private Placement (GlobeNewswire) +7.58%
Jun-01-23 05:19PM	Why Shares of Genelux Corporation Jumped This Week (Motley Fool) +6.62%
May-25-23 04:01PM	Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology (GlobeNewswire) +6.62%
May-15-23 07:00AM	Genelux Corporation Announces $33 Million Private Placement (GlobeNewswire) -9.06%
Mar-23-23 07:00AM	Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023 (GlobeNewswire)
09:00PM	Loading…
Jan-25-23 09:00PM	Genelux Corporation Announces Pricing of Initial Public Offering (GlobeNewswire)

Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Szalay Aladar	10% Owner	May 01 '24	Sale	3.30	33,061	109,161	1,195,731	May 01 06:16 PM
Szalay Aladar	10% Owner	Apr 30 '24	Sale	3.12	20,535	63,981	1,228,792	May 01 06:16 PM
Szalay Aladar	10% Owner	Apr 29 '24	Sale	3.25	6,403	20,792	1,249,327	May 01 06:16 PM
Szalay Aladar	10% Owner	Apr 24 '24	Sale	3.50	8,064	28,251	1,255,730	Apr 24 05:50 PM
Szalay Aladar	10% Owner	Apr 23 '24	Sale	3.49	22,000	76,800	1,263,794	Apr 24 05:50 PM
Szalay Aladar	10% Owner	Apr 22 '24	Sale	3.53	14,331	50,597	1,285,794	Apr 24 05:50 PM
Szalay Aladar	10% Owner	Apr 17 '24	Sale	3.71	22,737	84,425	1,300,125	Apr 18 05:00 PM
Szalay Aladar	10% Owner	Apr 16 '24	Sale	3.53	48,683	171,802	1,322,862	Apr 18 05:00 PM
Yu Yong	VP, Clinical Trial Operations	Dec 15 '23	Sale	13.16	32,535	428,180	0	Dec 18 04:15 PM
Thomas John	Director	Dec 13 '23	Sale	13.38	9,000	120,387	463,460	Dec 14 08:58 PM
Tyree James L	Director	Dec 13 '23	Sale	13.22	9,000	118,969	3,460	Dec 14 08:59 PM
Yu Yong	VP, Clinical Trial Operations	Dec 07 '23	Sale	11.85	36,800	435,995	32,535	Dec 08 05:57 PM
Yu Yong	VP, Clinical Trial Operations	Nov 21 '23	Sale	10.26	18,665	191,555	69,335	Nov 22 04:15 PM
Szalay Aladar	10% Owner	Oct 25 '23	Sale	19.40	5,704	110,638	1,371,545	Oct 26 05:07 PM
Yu Yong	VP, Clinical Trial Operations	Oct 24 '23	Option Exercise	6.00	5,200	31,200	111,335	Oct 25 04:15 PM
Yu Yong	VP, Clinical Trial Operations	Oct 24 '23	Sale	19.11	5,200	99,351	106,135	Oct 25 04:15 PM
Szalay Aladar	10% Owner	Oct 23 '23	Sale	19.97	49,987	998,365	1,377,249	Oct 25 04:51 PM
Thomas John	Director	Oct 16 '23	Sale	20.71	3,333	69,038	472,460	Oct 16 06:39 PM
Yu Yong	VP, Clinical Trial Operations	Oct 10 '23	Option Exercise	6.00	5,200	31,200	111,335	Oct 11 04:10 PM
Yu Yong	VP, Clinical Trial Operations	Oct 10 '23	Sale	22.01	5,200	114,462	106,135	Oct 11 04:10 PM
Szalay Aladar	10% Owner	Oct 05 '23	Sale	24.93	14,251	355,229	1,427,236	Oct 10 04:49 PM
Szalay Aladar	10% Owner	Oct 03 '23	Sale	25.49	75,690	1,929,225	1,441,487	Oct 04 06:43 PM
Szalay Aladar	10% Owner	Sep 28 '23	Sale	24.12	2,289	55,211	1,517,177	Sep 29 04:34 PM
Szalay Aladar	10% Owner	Sep 27 '23	Sale	24.47	11,257	275,459	1,519,466	Sep 29 04:34 PM
Yu Yong	VP, Clinical Trial Operations	Sep 26 '23	Option Exercise	6.00	5,200	31,200	111,335	Sep 27 04:10 PM
Szalay Aladar	10% Owner	Sep 26 '23	Sale	23.79	29,805	709,177	1,530,723	Sep 27 04:33 PM
Yu Yong	VP, Clinical Trial Operations	Sep 26 '23	Sale	23.56	5,200	122,528	106,135	Sep 27 04:10 PM
Szalay Aladar	10% Owner	Sep 25 '23	Sale	25.77	12,458	321,004	1,560,528	Sep 27 04:33 PM
Szalay Aladar	10% Owner	Sep 22 '23	Sale	27.33	9,042	247,123	1,572,986	Sep 25 06:30 PM
Szalay Aladar	10% Owner	Sep 21 '23	Sale	28.46	7,549	214,878	1,582,028	Sep 25 06:30 PM
Ryder Sean	General Counsel	Sep 20 '23	Option Exercise	6.00	10,000	60,000	10,572	Sep 21 04:30 PM
Yu Yong	VP, Clinical Trial Operations	Sep 20 '23	Option Exercise	6.00	6,000	36,000	112,135	Sep 21 04:35 PM
Ryder Sean	General Counsel	Sep 20 '23	Sale	30.00	10,000	300,000	572	Sep 21 04:30 PM
Yu Yong	VP, Clinical Trial Operations	Sep 20 '23	Sale	27.96	6,000	167,786	106,135	Sep 21 04:35 PM
Szalay Aladar	10% Owner	Sep 19 '23	Sale	26.45	32,167	850,942	0	Sep 20 04:48 PM
Szalay Aladar	10% Owner	Sep 18 '23	Sale	23.29	30,292	705,649	5,000	Sep 20 04:48 PM
Thomas John	Director	Sep 18 '23	Sale	24.99	3,334	83,317	475,793	Sep 18 08:12 PM
Yu Yong	VP, Clinical Trial Operations	Sep 15 '23	Option Exercise	6.00	10,400	62,400	116,535	Sep 18 08:13 PM
Yu Yong	VP, Clinical Trial Operations	Sep 15 '23	Sale	21.89	10,400	227,630	106,135	Sep 18 08:13 PM
Thomas John	Director	Sep 15 '23	Sale	21.90	3,333	72,996	479,127	Sep 18 08:12 PM
Szalay Aladar	10% Owner	Sep 14 '23	Sale	22.07	25,276	557,806	35,292	Sep 15 04:19 PM
Yu Yong	VP, Clinical Trial Operations	Sep 13 '23	Sale	21.14	29,800	629,927	106,135	Sep 15 08:06 PM
Szalay Aladar	10% Owner	Sep 13 '23	Sale	21.44	19,032	408,093	60,568	Sep 15 04:19 PM
Smither John W	Director	Sep 13 '23	Sale	20.78	900	18,702	6,920	Sep 14 08:18 PM
Szalay Aladar	10% Owner	Sep 12 '23	Sale	22.26	20,265	451,167	79,600	Sep 13 07:04 PM
Szalay Aladar	10% Owner	Sep 11 '23	Sale	22.22	32,351	718,702	99,865	Sep 13 07:04 PM
Szalay Aladar	10% Owner	Sep 08 '23	Sale	23.17	24,831	575,332	132,216	Sep 11 07:05 PM
Szalay Aladar	10% Owner	Sep 07 '23	Sale	24.37	12,446	303,268	157,047	Sep 11 07:05 PM
Yu Yong	VP, Clinical Trial Operations	Aug 30 '23	Sale	24.70	19,800	489,060	135,935	Aug 30 07:22 PM
Zindrick Thomas	President and CEO	Aug 18 '23	Sale	23.73	8,349	198,122	14,651	Aug 22 04:13 PM
Yu Yong	VP, Clinical Trial Operations	Aug 18 '23	Sale	23.73	3,265	77,478	155,735	Aug 22 04:14 PM
Cappello Joseph	VP, Pharmaceutical Development	Aug 18 '23	Sale	23.73	3,265	77,478	5,735	Aug 22 04:15 PM
Samuelson Doug	Chief Financial Officer	Aug 18 '23	Sale	23.73	1,297	30,778	2,303	Aug 22 04:17 PM
Smalling Ralph	Head of Regulatory	Aug 18 '23	Sale	23.73	935	22,188	2,065	Aug 22 04:18 PM
Jewett Caroline	Head of Quality	Aug 18 '23	Sale	23.73	515	12,221	1,135	Aug 22 04:18 PM
Ryder Sean	General Counsel	Aug 18 '23	Sale	23.73	328	7,783	572	Aug 22 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GNLX

Genelux Corp

Upgrade your FINVIZ experience